ESPR Esperion Therapeutics, Inc.

37.38
+0  (1%)
Previous Close 36.98
Open 37.06
Price To book 3.65
Market Cap 843.11M
Shares 22,555,000
Volume 645,728
Short Ratio 3.17
Av. Daily Volume 2,178,670

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced March 7, 2017. Data due 4Q 2017.
Bempedoic Acid/ Ezetimibe/ Atorvastatin (1002-038)
Hypercholesterolemia
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due mid 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
Bempedoic acid (ETC-1002-040)
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension